Found

What Found does

Found (Found Health, Inc.) is a US-based direct-to-consumer telehealth platform that delivers personalized obesity treatment, primarily through GLP-1 medications combined with clinical consultations, 1:1 health coaching, and a behavior change program. The platform targets adults with a BMI ≥30, or BMI ≥27 with a weight-related condition, connecting them to board-certified clinicians trained in obesity medicine via a web and mobile application. As of available data, Found has served over 300,000 lifetime members, booked more than 1 million clinician consultations, and reports an average 12% body weight loss across members over one year, with 83% sustaining results at twelve months.

The product surface is unusually broad for a weight care telehealth player: 10+ medications including compounded semaglutide and tirzepatide, branded GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro), oral GLP-1s (Rybelsus, Foundayo/orforglipron), and non-GLP-1 oral alternatives (metformin, topiramate, Contrave, bupropion/naltrexone). Differentiated features include a GLP-1 microdosing program, an exclusive in-app community, an insurance coverage checker, AI-powered chatbots for member support, and clinical protocols designed under a senior medical advisor and Chief Medical Officer. Clinical care is delivered through contracted medical groups (Pippen Health, Cloud Health Medical Group, SteadyMD) operating under Found ACE/OCHA arrangements for HIPAA-compliant care coordination.

Revenue is generated through recurring monthly subscriptions (Compounded GLP-1 Plan from $99/month, Generics Plan from $49/month, Branded GLP-1 Plan from $650/month), medication sales through partner pharmacies, insurance-billed clinical visits (sub-$30 copays for most members), and optional lab services. Customer acquisition runs through paid social (Meta), paid search, SEO, organic social on Instagram, TikTok, Facebook, and LinkedIn, content marketing, and referral programs. Distribution includes in-network relationships with six major US insurance carriers covering roughly 1 in 3 Americans, direct fulfillment partnerships with Novo Nordisk (NovoCare) and Eli Lilly (LillyDirect), and emerging B2B channels for employer-sponsored weight care benefits and health plan collaborations.

Name

Found

Legal name

Found Health, Inc.

Website

https://joinfound.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Short description

Found is a US-based telehealth platform delivering personalized weight loss treatment through GLP-1 medications, clinical consultations, and behavioral coaching. The company serves 300,000+ lifetime members via subscriptions, employer partnerships, and insurance networks covering 1 in 3 Americans.

Ownership category

akta.pro rank

Product category

Telehealth Weight Management

NAICS

Diet and Weight Reducing Centers (812191), Offices of Physicians (6211), Pharmacies and Drug Retailers (45611)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Obesity Medicine & Weight Management (HLAKADAL)

akta.pro secondary industries

Endocrinology & Diabetes Telemedicine Platforms (HLALAGAD), Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing (HLALAIAH), Copay Assistance, Patient Support & Affordability Programs (HLAEAKAI), Weight Management & Behavior Change Education (EDAAAHAF)

Keywords

• Weight loss medication
• Telehealth weight care
• GLP-1 prescriptions
• Obesity treatment
• Behavioral health coaching

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Subscription Fees (Membership): Monthly subscription fees for access to the platform, medical consultations, care coordination, and support services. Found offers Compounded GLP-1 plans, Generics plans, and Branded GLP-1 plans with varying price points. Subscription fees are not covered by insurance and are considered a Non-Covered Service.
2. Medication Sales: Revenue from dispensing compounded GLP-1 medications and facilitating branded GLP-1 prescriptions through partner pharmacies. Compounded medications are billed separately from subscription fees and are not covered by insurance.
3. Clinical Visit Fees (Insurance Billable): Medical consultations billed to insurance carriers for clinical visits. Most members pay less than $30/visit through insurance coverage. This is separate from the membership subscription fee.
4. Laboratory Services: Optional laboratory testing services offered to members, billed either through insurance or self-pay cash basis.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels10 records

Core offering

Found operates a direct-to-consumer telehealth weight care platform delivering personalized obesity treatment through board-certified clinicians, prescription medications (compounded GLP-1s, branded GLP-1s including Wegovy and Zepbound, the oral GLP-1 Foundayo/orforglipron, and non-GLP-1 options), a GLP-1 microdosing program, 1:1 health coaching, and an in-app community with behavior change support. Members access care through a web portal and mobile app, receive medications via partner pharmacies, and may use insurance coverage for clinical visits with most paying under $30 per visit.

Product overview

Found is a comprehensive telehealth weight care platform offering a unified ecosystem of clinical services, prescription medications, and digital support tools. The platform's core offering centers on GLP-1 medications (both branded and compounded formulations including semaglutide, tirzepatide, and the oral orforglipron/Foundayo), supported by telehealth consultations with obesity medicine specialists, 1:1 health coaching, and an app with community features and tracking tools. The platform operates on subscription-based plans (Compounded GLP-1 Plan, Generics Plan, and Branded GLP-1 Plan) that bundle clinical care, medications, and coaching services, with additional insurance navigation support.

Differentiator

Problem solved

Functional benefit

Brands

• Foundayo: Oral GLP-1 weight loss medication (orforglipron) offered by Found.

Products and services

• Found GLP-1 Weight Loss Program Telehealth weight care program offering GLP-1 medications (branded and compounded) along with clinical consultations, coaching, and app-based support tools for personalized weight loss treatment.
• GLP-1 Microdosing Program A simplified way to start GLP-1 medications using smaller doses, designed to help members begin treatment with potentially fewer side effects.
• Found App Mobile application providing in-app community support, expert-designed behavior change program, tracking tools, and access to care team communications.
• Telehealth Consultations Online medical consultations with board-certified providers specializing in obesity medicine for weight care treatment planning.
• Compounded Semaglutide Compounded version of semaglutide (GLP-1 receptor agonist) available for weight management, offered as an affordable alternative to brand-name versions.
• Compounded Tirzepatide Compounded version of tirzepatide (dual GIP/GLP-1 receptor agonist) for weight management, offered as an affordable alternative to brand-name options.
• Foundayo (Orforglipron) Oral GLP-1 weight loss medication (orforglipron), an oral small molecule GLP-1 receptor agonist approved for weight management, offering a non-injectable alternative.
• Ozempic (Semaglutide) FDA-approved brand-name semaglutide injection (GLP-1 receptor agonist) for weight management.
• Wegovy (Semaglutide) FDA-approved brand-name semaglutide injection specifically indicated for chronic weight management.
• Zepbound (Tirzepatide) FDA-approved brand-name tirzepatide injection (dual GIP/GLP-1 receptor agonist) for weight management.
• Mounjaro (Tirzepatide) FDA-approved brand-name tirzepatide injection for weight management.
• Saxenda (Liraglutide) FDA-approved brand-name liraglutide injection for weight management.
• Victoza (Liraglutide) FDA-approved liraglutide injection, prescribed off-label for weight management.
• Rybelsus (Semaglutide) FDA-approved oral semaglutide tablet for weight management.
• Trulicity (Dulaglutide) FDA-approved GLP-1 receptor agonist injection for weight management.
• Metformin FDA-approved oral medication typically used for diabetes, prescribed off-label for weight management.
• Contrave FDA-approved weight loss medication (bupropion/naltrexone combination) available through the platform.
• Topiramate Anti-epileptic medication prescribed off-label for weight management.
• Zonisamide Anti-seizure medication prescribed off-label for weight management.

Quantifiable outcome

• Up to 15-20% weight loss with Wegovy and Zepbound
• +5 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability4 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• United HealthcarecoreChannel Partner/ Reseller/ DistributorMajor insurance carrier partner accepting Found's weight care services. Coverage varies by state and plan.
• AetnacoreChannel Partner/ Reseller/ DistributorInsurance carrier partner providing coverage for Found's telehealth weight care services and medications.
• CignacoreChannel Partner/ Reseller/ DistributorInsurance carrier partner for weight care coverage through Found's platform.
• Blue Cross Blue ShieldcoreChannel Partner/ Reseller/ DistributorMajor insurance carrier partner covering Found's weight care services across multiple states.
• AnthemcoreChannel Partner/ Reseller/ DistributorInsurance carrier partner for weight management coverage through Found's telehealth platform.
• Highmark HealthcoreChannel Partner/ Reseller/ DistributorInsurance carrier partner providing coverage options in multiple states.
• Pippen Health (Delaware, California, Texas, New Jersey)coreStrategic or Co-development PartnerMedical groups contracted to provide telehealth medical consultations and secure messaging with patients. Part of Found ACE (Affiliated Covered Entity) for HIPAA compliance.
• Cloud Health Medical Group (PA, California, New Jersey, Kansas)coreStrategic or Co-development PartnerMedical groups participating in Found OCHA (Organized Health Care Arrangement) for joint care coordination and PHI sharing.
• SteadyMD Physician GroupminorStrategic or Co-development PartnerAffiliated medical group contracted to provide online telehealth medical consultations.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Ro: Ro operates the Ro Body Program, a direct-to-consumer telehealth weight loss offering with compounded and branded GLP-1s, telehealth consultations, and coaching. Ro is the most directly comparable platform to Found across product breadth, GTM motion, and pricing structure.
• Hims & Hers Health: Hims & Hers offers telehealth weight loss programs including branded and compounded GLP-1s alongside its broader men's and women's health verticals. The company is a direct competitor with overlapping customer acquisition channels and a comparable subscription model.
• Calibrate: Calibrate is a metabolic health and weight loss telehealth platform pairing GLP-1 prescribing with behavior change coaching on a subscription basis. Comparable to Found's combined medication-plus-coaching model.
• Noom: Noom combines behavior change programs with newer telehealth medication offerings including GLP-1s. It competes with Found on the same weight-loss consumer target through an app-based coaching-first approach.
• LifeMD: LifeMD is a telehealth platform offering weight management programs including GLP-1 medications through its direct-to-consumer brands. It is a comparable smaller-scale direct competitor.

Broad incumbents

• WeightWatchers (WW): WW expanded into telehealth weight management via its acquisition of Sequence and now offers GLP-1 prescribing alongside its established points-based program. WW is a broad incumbent with overlapping but differentiated offerings.
• Teladoc Health: Teladoc is a broad telehealth incumbent with chronic condition management offerings that increasingly overlap with obesity care. Comparable as a telehealth infrastructure and chronic care competitor, though not weight-loss specialized.
• Amwell: Amwell provides enterprise telehealth infrastructure and chronic care programs used by payers and providers. It overlaps with Found indirectly through payer-partnered virtual care delivery rather than direct-to-consumer weight loss.

Emerging players

• Eli Lilly (LillyDirect): LillyDirect is Eli Lilly's direct-to-patient platform for dispensing Zepbound and other GLP-1s. It is both a partner and emerging competitive threat as it potentially disintermediates telehealth platforms on branded medication fulfillment.
• Mochi Health: Mochi Health is an emerging obesity-medicine telehealth platform offering GLP-1 prescribing and care coordination. It targets the same patient segment as Found with a comparable weight-care-focused model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/joinfoundhealth
• LinkedInlinkedin.com/company/joinfound1
• Instagraminstagram.com/joinfound
• TikToktiktok.com/@joinfound
• Xx.com/joinfoundhealth

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Found